<![CDATA[Rhizen Pharmaceuticals AG 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=37028>Sun, 19 Apr 2026 11:16:06 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Rhizen Pharmaceuticals AG Announces Upcoming Data Presentations at ESMO 2022 for Its Clinical Stage Assets; Tenalisib in Locally Advanced/ Metastatic Breast Cancer and RP12146 in Multiple Solid Tumors]]>https://www.newswire.co.kr/newsRead.php?no=951131Tue, 13 Sep 2022 16:40:00 +0900<![CDATA[리젠 파마슈티컬스, ESMO 2022서 테날리십의 국소 진행성 및 전이성 유방암 치료 효과 및 RP12146의 다발성 고형암 치료 효과 데이터 공개 예정]]>https://www.newswire.co.kr/newsRead.php?no=951140Tue, 13 Sep 2022 16:40:00 +0900<![CDATA[Rhizen Pharmaceuticals AG Announces Promising Interim Data Presentation >From an Ongoing Phase II Study of Tenalisib (RP6530) in Locally Advanced or Metastatic Breast Cancer Patients At ESMO Breast Cancer Meeting 2022]]>https://www.newswire.co.kr/newsRead.php?no=944007Fri, 06 May 2022 09:40:00 +0900<![CDATA[리젠 파마슈티컬스, 2022년 ESMO 유방암 학회서 국소 진행성 또는 전이성 유방암 환자 대상 테날리십(RP6530) 임상 2상 시험의 유망 중간 데이터 발표]]>https://www.newswire.co.kr/newsRead.php?no=944008Fri, 06 May 2022 09:40:00 +0900<![CDATA[Rhizen Pharmaceuticals AG Presents Data on Its Differentiated PARP and DHODH Inhibitor Programs at AACR 2022]]>https://www.newswire.co.kr/newsRead.php?no=942508Mon, 11 Apr 2022 11:00:00 +0900<![CDATA[리젠 파마슈티컬스, AACR 2022 회의서 차별화한 PARP 및 DHODH 억제제 프로그램 데이터 제시]]>https://www.newswire.co.kr/newsRead.php?no=942509Mon, 11 Apr 2022 11:00:00 +0900<![CDATA[Rhizen Pharmaceuticals AG Announces First Patient Dosing in a Phase I/Ib Study of Its Novel PARP Inhibitor (RP12146) in Patients With Advanced Solid Tumors]]>https://www.newswire.co.kr/newsRead.php?no=933476Tue, 02 Nov 2021 15:30:00 +0900<![CDATA[리젠 파마슈티컬스, 새로운 PARP 억제제(RP12146) I/Ib상 연구에서 진행성 고형암 환자에 첫 투약]]>https://www.newswire.co.kr/newsRead.php?no=933477Tue, 02 Nov 2021 15:30:00 +0900<![CDATA[Rhizen Pharmaceuticals AG Announces First Patient Dosing in a Phase II Study of Tenalisib (RP6530) in Locally Advanced or Metastatic Breast Cancer Patients]]>https://www.newswire.co.kr/newsRead.php?no=932241Thu, 14 Oct 2021 17:55:00 +0900<![CDATA[리젠 파마슈티컬스, 국소 진행성 또는 전이성 유방암 환자 대상 테날리십(RP6530) 2상 연구의 첫 환자 투약]]>https://www.newswire.co.kr/newsRead.php?no=932242Thu, 14 Oct 2021 17:55:00 +0900<![CDATA[Rhizen Pharmaceuticals AG Announces First Patient Dosed in a Phase 2 Study of RP7214 in Covid-19 Patients]]>https://www.newswire.co.kr/newsRead.php?no=930955Fri, 24 Sep 2021 14:30:00 +0900<![CDATA[리젠 파마슈티컬스, DHODH 억제제 ‘RP7214’ 임상 2상 코로나19 환자에 첫 투약]]>https://www.newswire.co.kr/newsRead.php?no=930956Fri, 24 Sep 2021 14:30:00 +0900<![CDATA[Rhizen Pharmaceuticals AG Announces That Its Partnered Asset, Umbralisib (UKONIQ™), Has Received US FDA Accelerated Approval for Adult Patients With Relapsed or Refractory MZL & FL]]>https://www.newswire.co.kr/newsRead.php?no=918478Wed, 10 Feb 2021 15:30:00 +0900<![CDATA[리젠 파마슈티컬스, 라이선스 제공한 자산인 움브럴리시브(UKONIQ™)가 미국 FDA로부터 성인 재발성/불응성 MZL 및 FL 환자들에 대한 치료제로 신속 승인 받았다고 발표]]>https://www.newswire.co.kr/newsRead.php?no=918480Wed, 10 Feb 2021 15:30:00 +0900